Pallas Health vs Ro.co: Clinician-led compounded plans vs Wegovy pill
The Pallas Health vs Ro.co comparison comes down to one clear split: Pallas lets a US-licensed clinician choose between FDA-approved brand pens and clinician-personalized compounded injectables, while Ro.co provides access to the FDA-approved Wegovy pill and a $39 online start. Early verdict: choose Pallas Health if you want clinician-driven access to both brand and compounded injectables; choose Ro.co if you need an FDA-approved oral option or a low cost to begin.
View Pallas clinician-selected plans
Direct comparison overview: treatment routes and regulatory status
Both platforms provide online clinician review, but they differ on the medication routes and regulatory framing. Pallas Health offers FDA-approved brand-name injectables such as Wegovy, Ozempic, Zepbound and Mounjaro when appropriate, and clinician-personalized compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. Ro.co is the only platform here offering the FDA-approved Wegovy pill, an oral GLP-1, and presents that finished medication as not compounded.
Five key differences that matter
1. Medication form and regulatory clarity
Pallas Health: clinician may prescribe FDA-approved pens or compounded injectables. Regulatory note for Pallas: compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Pallas states compounded medications are prepared by US-licensed compounding pharmacies and may differ in appearance from site images.
Ro.co: offers the Wegovy pill, described as an FDA-approved finished oral product. Ro emphasizes that offering the oral option is significant for patients who are injection-averse and notes that treatment is available only when a licensed clinician determines it is medically appropriate.
2. Starting price and ongoing pricing structure
Pallas Health lists compounded semaglutide at $139 for the first month, then $597 every 12 weeks which the company frames as a $199 per month average. Compounded tirzepatide is $179 first month, then $897 every 12 weeks, a $299 per month average. Pallas also lists brand-name cash-pay monthly figures for Wegovy, Zepbound, Ozempic and Mounjaro on captured pages.
Ro.co advertises you can get started online for just $39. Ro warns that ongoing branded medication pricing depends on the treatment plan and medication prescribed and that branded medications typically cost more than compounded alternatives.
3. How pricing reacts to titration and plan structure
Pallas prices its compounded plans by medication rather than by milligram, so according to Pallas the plan price does not increase as the dose is titrated. Pallas notes compounded plans renew every 12 weeks rather than monthly and that cancellation timing matters. Ro.co states pricing is disclosed before you complete the consultation and emphasizes no hidden fees, but ongoing costs for branded medications can be high.
4. Eligibility, clinician review and platform model
Pallas is 100% online with clinician review; eligibility is determined by a US-licensed clinician. Pallas is asynchronous in most states with a video visit required in seven states plus Washington, D.C. Ro.co also uses licensed clinicians and makes the Wegovy pill available when medically appropriate. Ro presents itself as an established, full-service platform with brand trust.
5. Shipping, membership and support differences
Pallas includes provider care, ongoing check-ins and care-team messaging inside the plan price with no separate membership fee and offers free expedited discreet shipping on every plan. Pallas care-team hours are weekdays 9 AM to 5 PM ET and no emergency services are offered. Ro.co highlights no hidden fees and that pricing is disclosed up front; captured landing page did not verify shipping or membership details.
| Criteria | Pallas Health | Ro.co |
|---|---|---|
| Primary medication options | Brand-name pens plus compounded semaglutide or tirzepatide | Wegovy pill and branded medications |
| Starting price | $139 first month for compounded semaglutide | $39 to get started online |
| Regulatory note | Compounded meds are not FDA-approved; prepared by US compounding pharmacies | Wegovy pill is FDA-approved finished medication |
| Pricing model | Compounded plans priced by medication; renew every 12 weeks | Start $39; ongoing branded pricing varies by plan and medication |
| Care and shipping | Provider care included, no membership fee, free expedited shipping | No hidden fees claimed; shipping and membership not verified on captured page |
How to choose between Pallas Health and Ro.co
Use the differences above to match to your priorities. Pallas Health centers clinician choice between brand pens and compounded injectables, includes provider care in the plan price, and presents a compounded semaglutide introductory price of $139 then a $199 per month average. Ro.co centers access to the FDA-approved Wegovy pill, highlights a $39 online start, and positions the oral option as the primary advantage for injection-averse patients.
Check Pallas compounded and brand options
Start Pallas intake with clinician review
Final thoughts on Pallas Health vs Ro.co
Primary keyword recap: Pallas Health vs Ro.co is fundamentally a choice between clinician-personalized access to brand or compounded injectables with Pallas and the Wegovy oral FDA-approved route with Ro.co. If you value a clinician to choose between brand pens and a compounded injectable plan and want provider care included in the plan price, Pallas Health matches that need. If you need an FDA-approved oral GLP-1 or a low-cost online entry point, Ro.co offers that path.
Choose Pallas Health if…
You want a US-licensed clinician to pick between brand-name pens and compounded semaglutide or tirzepatide, prefer provider care and messaging included in plan pricing, and want compounded plans priced by medication rather than by milligram.
Choose Ro.co if…
You need access to the FDA-approved Wegovy pill for an injection-free option, want to start online for $39, and prioritize an FDA-approved finished oral medication over compounded injectables.